Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Gerald Pier
Brigham and Women's Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
OneBiopharma
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Pier owns equity in OneBiopharma as a co-founder. OneBiopharma is the functional successor to Alopexx Pharmaceuticals and as a sublicensee of Alopexx's intellectual property, which was invented by Dr. Pier, it continues Alopexx's work of developing an alternative to antibiotics for the treatment and prevention of staphylococcal and other serious bacterial infections. The company also develops vaccines. The research project looks at infections caused by Pseudomonas aeruginosa and the plethora of pathogens causing keratitis and conjunctivitis that express the broadly conserved surface polysaccharide poly-N-acetyl glucosamine (PNAG), and is investigating the use of a PNAG antibody to treat bacterial infections of the eye. Since the company's intellectual property regarding both the antibody and the vaccine is being investigated in the project and the value of both could be affected by the results of the project, it is reasonable to conclude that the results of the project could affect the financial interests of the company.
Pathogenesis of microbial anterior eye diseases
Eye infections are the leading cause of blindness worldwide and thus prevention and treatment with new therapies based on insights into the means used by microbes to cause eye infections should enhance the medical community's ability to prevent blindness. One component of this project will study vaccine-based approaches in mice for preventing or treating a broad range of infectious eye disease by targeting a conserved component found on the surface of many infectious agents. These results will justify testing of the vaccine in humans. Another approach uses modern cutting edge DNA sequencing technology to understand how the leading cause of contact lens infections is able to do so in the eye in order to gain a more detailed and precise insight into the infectious nature of this microbe.
Filed on July 25, 2019.
Tell us what you know about Gerald Pier's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Gerald Pier filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Gerald Pier | Brigham and Women's Hospital | Conflict of Interest | Aridis Pharmaceuticals | $150,000 - $199,999 |
| Gerald Pier | Brigham and Women's Hospital | Conflict of Interest | Alopexx Pharmaceuticals/Alopexx Vaccines | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.